A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia-Reference-Cited by-同舟云学术

A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia

Published:2012-01-31 Issue:7 Volume:53 Page:1331-1337
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Foster Matthew C.,Amin Chirag,Voorhees Peter M.,van Deventer Hendrik W.,Richards Kristy L.,Ivanova Anastasia,Whitman Jennifer,Chiu Wingkeung Michael,Barr Nathan D.,Shea Thomas

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2011.647313

Reference43 articles.

1. Biology and management of relapsed acute myeloid leukaemia

2. Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure

3. Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia

4. Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

5. Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Handling Incomplete or Late-Onset Toxicities in Early-Phase Dose-Finding Clinical Trials: Current Practice and Future Prospects;JCO Precision Oncology;2024-02

2. Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer;BMC Cancer;2021-07-05

3. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults;Expert Opinion on Biological Therapy;2020-10-05

4. Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer;2020-08-21

5. A Bayesian model‐free approach to combination therapy phase I trials using censored time‐to‐toxicity data;Journal of the Royal Statistical Society: Series C (Applied Statistics);2018-11-22